Groundbreaking Libevitug Injection Approved in China for Treating Hepatitis D Huahui Health's Libevitug injection has received conditional approval in China as a breakthrough treatment for chronic hepatitis D, addressing an urgent medical need.

Groundbreaking Libevitug Injection Approved in China for Treating Hepatitis D #China #Beijing #Hepatitis_D #Huahui_Health #Libevitug

Ribo Receives EMA Orphan Drug Status for RBD1016 Against Hepatitis D Infection Ribo Life Science's siRNA therapy RBD1016 has been granted Orphan Drug Designation by the EMA for treating Hepatitis D, enhancing its development potential.

Ribo Receives EMA Orphan Drug Status for RBD1016 Against Hepatitis D Infection #China #Suzhou #Ribo_Life_Science #RBD1016 #Hepatitis_D